On recordAs of Nov 16, 2026
Amedisys no longer trades under AMED.
The filings below run to Sep 12, 2025.

Congress trades
No longer trading under AMED.
5 Congress trades · last filed Sep 12, 2025
Free on iOS and Android
Email me new Amedisys filings
FREE. An email on days Amedisys insiders file a trade or Amedisys reports results. One a day at most.
Check your inbox
We sent a link to your address. Tap it to confirm; we email nothing until you do.
Want it the moment it is filed? The app sends a push, free.
On recordAs of Nov 16, 2026
Amedisys no longer trades under AMED.
The filings below run to Sep 12, 2025.
EarningsQ2 FY2025 · reported Jul 29, 2025
Q2 FY2025: Beat on EPS. Revenue missed by 2.2%.
EPS Q2 FY2025
Revenue Q2 FY2025
Beat 4 · Miss 2
CongressSTOCK Act disclosures to the House and Senate
5 Congress disclosures shown, from 2 members.
| Quarter | EPS | EPS expected | Revenue | Revenue expected | Result |
|---|---|---|---|---|---|
| Q2 FY2025reported Jul 29, 2025 | $1.54 | $1.39 | $621.9M | $635.8M | EPS beatRevenue miss |
| Q1 FY2025reported Apr 23, 2025 | $1.25 | $1.13 | $594.8M | $612.0M | EPS beatRevenue miss |
| Q4 FY2024reported Feb 26, 2025 | $0.96 | $1.05 | $598.1M | $602.4M | EPS missRevenue in line |
| Q3 FY2024reported Nov 6, 2024 | $1.00 | $1.17 | $587.7M | $596.4M | EPS missRevenue in line |
| Q2 FY2024reported Jul 24, 2024 | $1.32 | $1.22 | $591.2M | $578.8M | EPS beatRevenue beat |
| Q1 FY2024reported Apr 24, 2024 | $1.03 | $1.01 | $571.4M | $565.4M | EPS beatRevenue in line |
Actual against the consensus estimate at the time. A flag marks a beat or a miss of more than 1.5% either way; inside that band the quarter is in line. A flag reads n/a only when a number is missing. An estimate is a forecast made by analysts, not a company target.
Since the trade: the stock's move from its estimated entry price (a purchase) or estimated exit price (a sale) to its current price, the latest close we hold. Not the member's result.
| Member | Type | Action | Amount disclosed | Since the trade | Trade date | Disclosed | Delay |
|---|---|---|---|---|---|---|---|
| Stock | Sale | $1,001 - $15,000 | n/aPrice history ends Aug 14, 2025 | Aug 18, 2025 | Sep 12, 2025 | 25d | |
| Stock | Purchase | $1,001 - $15,000 | n/aPrice history ends Aug 14, 2025 | Jun 9, 2025 | Aug 13, 2025 | 65d | |
| Stock | Sale | $1,001 - $15,000 | n/aPrice history ends Aug 14, 2025 | Mar 14, 2023 | Apr 7, 2023 | 24d | |
| Stock | Purchase | $1,001 - $15,000 | n/aPrice history ends Aug 14, 2025 | Feb 10, 2023 | Mar 3, 2023 | 21d | |
| Stock | Purchase | $1,001 - $15,000 | n/aPrice history ends Aug 14, 2025 | Jan 11, 2023 | Feb 7, 2023 | 27d |
We hold no closing prices for any row shown here, so no move is shown. Not investment advice.
Estimated prices are the stock's closing price on the trade date. A disclosure gives a value band, not the price paid. Not investment advice. After a sale a positive figure means the stock kept rising after it. On an option line the prices are the stock's, never the option's: the premium is never disclosed.
A delay above 45 days is the gap between the dates on the report; we mark a filing late only after checking it.
"Not captured" means the band or the transaction type on the original report is missing from our data.
"Dates conflict" marks a row whose disclosure is dated before its trade on the record we hold. Both dates are printed as filed, and no prices or move are shown for that row.
Every Congress trade in AMED filterable by party, chamber, type and account.
Congress rows disclose a value range rather than an exact amount, and the STOCK Act allows up to 45 days to report. Full sourcing and the limits of this data are on the methodology page. A filing is a record of a transaction, not a signal, and nothing here is investment advice.
A STOCK Act disclosure gives each trade as a band of dollar values, which we do not narrow, and is due within 45 days of the trade. An option is described by its underlying company's name; its row says it is an option.
Data as of Nov 16, 2026.
What the filings on AMED show and how current they are.
Lisa C. McClain and Ro Khanna disclosed AMED transactions in the filings shown here.
Congressional disclosures took a median of 25 days, against the 45 the STOCK Act allows.